» Articles » PMID: 36552960

PVR-A Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma

Overview
Specialty Radiology
Date 2022 Dec 23
PMID 36552960
Authors
Affiliations
Soon will be listed here.
Abstract

The poliovirus receptor (PVR) is a member of the immunoglobulin superfamily (Ig SF) and is essential for the promotion of cancer cell proliferation and invasion. However, the correlation between PVR expression and prognosis as well as immune infiltration in hepatocellular carcinoma (HCC) remains unclear. The expression level of PVR was quantified using the Tumor and Tumor Immunity Evaluation Resource (TIMER) and Sangerbox. The Gene Expression Omnibus (GEO) database was used to validate the PVR expression. The receiver operating characteristic (ROC) curve was used to evaluate the feasibility of using PVR as a differentiating factor according to the area under curve (AUC) score. A PVR binding protein network was built using the STRING tool. An enrichment analysis using the R package clusterProfiler was used to explore the potential function of PVR. Immune infiltration analysis was calculated with ESTIMATE algorithms. We also assessed the correlation between PVR expression and immune infiltration by the single-sample Gene Set Enrichment Analysis (ssGSEA) method from the R package GSVA and TIMER database. The results showed that PVR was commonly overexpressed in multiple types of tumors including HCC. The data of GSE64041 confirmed the same result. The ROC curve suggested that PVR could be a potential diagnostic biomarker. Additionally, high mRNA expression of PVR in HCC was significantly correlated with poor overall survival (OS) and relapse free survival (RFS). Results also indicated correlations between PVR mRNA expression with the level of infiltration immune cells including B cells, CD8+ T cells, cytotoxic cells, DCs, CD56dim NK cells, pDCs, and Th2 cells. Furthermore, the PVR level was significantly correlated with immune markers for immunosuppressive cells in HCC. In conclusion, PVR might be an important regulator of tumor immune cell infiltration and a valuable prognostic biomarker in HCC. However, additional work is needed to fully elucidate the underlying mechanisms.

Citing Articles

Analysis of the progression of cervical cancer in a low-and-middle-income country: From pre-malignancy to invasive disease.

Robinson E, Rodriguez I, Argueta V, Xie Y, Lou H, Milano R Tumour Virus Res. 2024; 19():200299.

PMID: 39672307 PMC: 11729683. DOI: 10.1016/j.tvr.2024.200299.


Deciphering Natural Killer Cell Cytotoxicity Against Medulloblastoma in vitro and in vivo: Implications for Immunotherapy.

Gauthier M, Pierson J, Moulin D, Mouginot M, Bourguignon V, Rhalloussi W Immunotargets Ther. 2024; 13:319-333.

PMID: 38948503 PMC: 11214763. DOI: 10.2147/ITT.S458278.


A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12).

Lee D, Park S, Kim Y, Lee Y, Shin S, Ahn B Oncoimmunology. 2024; 13(1):2371563.

PMID: 38919826 PMC: 11197908. DOI: 10.1080/2162402X.2024.2371563.


LARS1 is a Prognostic Biomarker and Exhibits a Correlation with Immune Infiltrates in Hepatocellular Carcinoma.

Fan L, Qin Z, Wu D, Yang Y, Zhang Y, Xie B Int J Gen Med. 2024; 17:2203-2221.

PMID: 38774724 PMC: 11107939. DOI: 10.2147/IJGM.S457577.


DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.

Cifaldi L, Melaiu O, Giovannoni R, Benvenuto M, Focaccetti C, Nardozi D Front Immunol. 2023; 14:1197053.

PMID: 37359555 PMC: 10285446. DOI: 10.3389/fimmu.2023.1197053.

References
1.
Li W, Liu K, Chen Y, Zhu M, Li M . Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance. Curr Med Chem. 2020; 28(6):1126-1142. DOI: 10.2174/0929867327999200729151247. View

2.
Nakai R, Maniwa Y, Tanaka Y, Nishio W, Yoshimura M, Okita Y . Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci. 2010; 101(5):1326-30. PMC: 11158505. DOI: 10.1111/j.1349-7006.2010.01530.x. View

3.
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Braun M, Aguilera A, Sundarrajan A, Corvino D, Stannard K, Krumeich S . CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8 T Cells. Immunity. 2020; 53(4):805-823.e15. DOI: 10.1016/j.immuni.2020.09.010. View